Acquisition Announced Sponsor buyer
Veloxis Pharmaceuticals acquisition of AiCuris Anti-infective Cures AG
€780m consideration
Announced 26 Feb 2026
Advisers
AiCuris Anti-infective Cures AG
Target
Veloxis Pharmaceuticals
Acquirer
- Legal adviser
- Freshfields
Team: Lars Meyer, Vasco Ollero, Jil Rollmann, Benedikt Grosch, Christian Ruoff, Michael Ramb, Philipp Dohnke, Christoph Werkmeister, Frank Schaer, Gerrit Beckhaus, Stephan Denk, Philipp Lehmann, Uwe Salaschek, Lukas Pomaroli, Jordan Salzman, Tobias Franz, Maximilian Zellerhoff, Nicolas Sölter, Malte Symann, Oliver Neuner, Lorena Faggioli, Julia Sommer, Leonhard Ackermann, Lennart Meyer, Steven Baier, Lina Zhu
- Target
- AiCuris Anti-infective Cures AG
- Acquirer
- Veloxis Pharmaceuticals
- Sponsor
- Asahi Kasei Group
- Target based in
- Germany
- Buyer based in
- United States
- Sector
- Pharma
- Tags
- Pharma, Drug Development
In the league tables
Similar deals
- Eli Lilly and Company acquisition of Ventyx Biosciences Jan 2026 · US$1.2bn · Biotech
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech
- Shionogi & Co. acquisition of Shionogi-Apnimed Sleep Science Apr 2026 · US$100m · Pharma
- Tarsus Pharmaceuticals acquisition of iRenix Medical Jul 2026 · US$75m · Ophthalmology
- Hansoh Pharmaceutical Group Co. stake in Avere Therapeutics Jul 2026 · Biotech
Sources
- 26 Feb 2026 Freshfields advises Veloxis and Asahi Kasei on €780m acquisition of AiCuris freshfields.com
- 27 Feb 2026 Gibson Dunn Advises Shareholders in Connection with Sale of Aicuris to Asahi Kasei gibsondunn.com
